Title and Organization:
Dipal Doshi is the president and chief executive officer of Entrada Therapeutics, a biotechnology company focused on the treatment of devastating diseases through the intracellular delivery of biologics. Mr. Doshi also serves on Entrada’s Board of Directors. Prior to this role, Mr. Doshi served as the chief business officer for Amicus Therapeutics (FOLD) where he led Amicus’ business and corporate development, global strategy, new product planning and commercial planning functions. Prior to Amicus, Mr. Doshi was the senior vice president at Auven Therapeutics, a healthcare private equity fund. Mr. Doshi has also held corporate development and operating roles at Catalent Pharma Solutions and was also a member of Merrill Lynch's Investment Banking Group. Prior to receiving his MBA, Mr. Doshi held roles at Eli Lilly and Sapient Corporation (Publicis). Mr. Doshi serves as a member of the Board of Directors for the Children's Health Fund. Mr. Doshi received a BA from Rutgers University and an MBA from The Wharton School of the University of Pennsylvania. Dipal is a Fellow of the second class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.